Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI
Ngày 21/12/2020 02:42 | Lượt xem: 104

A subgroup analysis of the ISAR REACT-5—Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5—trial has found that among patients with ST-segment–elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) receiving either prasugrel or ticagrelor, there was no significant difference in combined rates of death, myocardial infarction, or stroke at one year.

The analysis, authored by Alp Aytekin (Universität München, Munich, Germany) and colleagues, published in Circulation, also concluded that ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction.

In the study, Aytekin and colleagues note that data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with STEMI undergoing primary PCI are limited.

The pre-specified subgroup analysis included 1,653 patients with STEMI randomised to receive ticagrelor or prasugrel in the setting of the ISAR REACT-5 trial. The primary endpoint was the incidence of death, myocardial infarction, or stroke at one year after randomisation. The secondary endpoint was the incidence of bleeding defined as BARC (Bleeding Academic Research Consortium) type 3‒5 bleeding at one year after randomisation.

Detailing the results, Aytekin and colleagues note that the primary endpoint occurred in 83 patients (10.1%) in the ticagrelor group and in 64 patients (7.9%) in the prasugrel group (hazard ratio, 1.31 [95% CI, 0.95–1.82]; P=0.10). One-year incidence of all-cause death (4.9% versus 4.7%; P=0.83), stroke (1.3% versus 1.0%; P=0.46), and definite stent thrombosis (1.8% versus 1.0%; P=0.15) did not differ significantly in patients assigned to ticagrelor or prasugrel, they note.

One-year incidence of myocardial infarction (5.3% versus 2.8%; hazard ratio, 1.95 [95% CI, 1.18–3.23]; P=0.010) was higher with ticagrelor than with prasugrel, the authors note, adding that BARC type 3‒5 bleeding occurred in 46 patients (6.1%) in the ticagrelor group and in 39 patients (5.1%) in the prasugrel group (hazard ratio, 1.22 [95% CI, 0.80–1.87]; P=0.36).

In their conclusion, the authors state: “In patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention, there was no significant difference in the primary endpoint between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction.”

Source CardiovascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua google bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua twitter bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua MySpace bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua LinkedIn bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua stumbleupon bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua icio bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua digg bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua yahoo bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua yahoo bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua yahoo bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI Chia sẽ qua yahoo bài: Analysis of STEMI patients finds little difference between prasugrel and ticagrelor after PCI

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP